EGFR and non-small cell lung carcinoma: In patients with multiple BMs from epidermal growth factor receptor (EGFR)‐mutant NSCLC, EGFR‐TKIs were associated with significantly longer intracranial progression‐free survival (PFS) than with WBI.10